Suggestions
Carri Duncan
Founder Karaktero Capital - Digital Health Investor - Advisory Board Member - Public Speaker
Professional Background
Carri Duncan, Ph.D., is a distinguished finance executive with over a decade of experience specializing in life sciences and healthcare. Her expertise uniquely marries her scientific background with her extensive finance knowledge, enabling her to bridge the gap between cutting-edge research and strategic investment opportunities. Currently, Dr. Duncan plays a pivotal role in Investor Relations at Bayer, representing one of the foremost players in the global pharmaceutical sector.
Throughout her illustrious career, Carri has consistently worked alongside C-suite executives of leading multinational corporations, leveraging her vast professional network that includes founders, investors, family foundations, and corporate leaders. This esteemed network has been pivotal in helping to finance and champion innovative ideas that are poised to impact healthcare and medicine significantly. Dr. Duncan's mantra—focusing on data-driven strategies rather than bias—reflects her commitment to an ethical approach in financing impactful healthcare initiatives.
Her previous roles demonstrate her versatility and deep understanding of the financial landscape within the life sciences sector. Carri has honed her analytical skills as a Senior Healthcare Analyst at Macquarie Group and made significant contributions as a Buy-Side Equity Analyst at Credit Suisse, where she focused on biotechnology investments. These experiences have equipped her with a robust understanding of market dynamics and investment strategies that drive the success of initiatives in the healthcare landscape.
Beyond finance and analytics, Dr. Duncan's passion for healthcare innovation is evident from her tenure as a Research Scientist at Novartis, where she contributed to groundbreaking research that advances medical science. Additionally, her previous roles as a Legislative Intern at the United States Senate and Vice-Chairperson at Yebn Switzerland showcase her commitment to public health initiatives and the integration of policy with healthcare financing.
Education and Achievements
Carri Duncan received her Ph.D. in Biological Sciences, which laid a strong foundation for her expertise in both science and finance. Her academic training was further refined during her graduate studies at the Department of Energy Plant Research Lab at Michigan State University, where she engaged in innovative research that enhanced her scientific acumen and data analysis skills.
Dr. Duncan’s accomplishments go beyond her professional roles, encompassing a variety of partnerships and projects that aim to enhance healthcare outcomes worldwide. Her dedication to leveraging finance for the betterment of health challenges the status quo and encourages a new generation of investment strategies centered on sustainability and social impact.
Dr. Duncan's work is characterized by her curiosity and commitment to supporting agendas that improve medicine and healthcare. She is known for her ability to identify and nurture the best ideas, ensuring they receive the financial backing they need to flourish. With a keen eye for groundbreaking research and innovations, Carri has become a trusted advisor and partner for many organizations seeking to navigate the complex world of life sciences financing.
Achievements
- Investor Relations Management at Bayer: Developed and maintained strategic relationships with key stakeholders, facilitating informed investment decisions in life sciences.
- Consultant at Egon Zehnder: Provided management consulting services that harnessed her dual expertise in science and finance, enhancing client outcomes in the healthcare sector.
- Top Analyst Roles: Achieved recognition as a top healthcare analyst at both Macquarie Group and Credit Suisse, leading successful buy-side equity analyses that influenced major investment decisions.
- Biotech Investment Evaluation: In her role as a Biotech Equity Analyst at May Davis Group, Carri Duncan successfully evaluated and recommended investment opportunities that capitalized on biotech innovations.
- Legislative Intern Contributions: While interning at the United States Senate, she contributed to healthcare policy discussions that informed legislative priorities, enhancing her understanding of the intersection between policy and healthcare finance.
- Leadership Role at Yebn Switzerland: As Vice-Chairperson, she advocated for youth engagement in biotechnology and healthcare discussions, fostering a new generation of leaders in these vital sectors.
- Research Scientist at Novartis: Conducted impactful research that contributed to novel solutions in healthcare, solidifying her commitment to advancing medicine.
Dr. Carri Duncan continues to lead the charge in integrating financial strategies with innovative healthcare solutions, continuously seeking opportunities to support initiatives that prioritize patient care and sustainable health advancements.
